AOP-Wiki

API

All Key Events

Showing 1826 to 1850 of 1947 Key Events

ID	Title	Event Component Count	Biological Organization	Created At	Last Updated	AOPs

584	Inhibition, sodium channel Short Name Inhibition, sodium channel	2	Molecular	Nov 29, 2016	Sep 16, 2017	5 AOPs 91: Sodium channel inhibition leading to reduced survival 93: sodium channel inhibition leading to increased predation 94: Sodium channel inhibition leading to congenital malformations 197: Sodium channel (Nav1.1) inhibition leading to population decline 553: Inhibition of Voltage-gated sodium channels (Na⁺ channels) leading to heart failure
520	Decreased sperm quantity or quality in the adult, Decreased fertility Short Name	4	Individual	Nov 29, 2016	Dec 3, 2016	5 AOPs 70: Modulation of Adult Leydig Cell Function Subsequent to Proteomic Alterations in the Adult Leydig Cell 71: Modulation of Adult Leydig Cell Function Subsequent to Glucocorticoid Activation 64: Glucocorticoid Receptor (GR) Mediated Adult Leydig Cell Dysfunction Leading to Decreased Male Fertility 476: Adverse Outcome Pathways diagram related to PBDEs associated male reproductive toxicity 595: Emerging OPFRS reproductive outcome pathway
1901	Interferon-I antiviral response, antagonized by SARS-CoV-2 Short Name IFN-I response, antagonized	3	Cellular	Jul 9, 2021	Dec 15, 2023	5 AOPs 430: Binding of SARS-CoV-2 to ACE2 leads to viral infection proliferation 422: Binding of SARS-CoV-2 to ACE2 in enterocytes leads to intestinal barrier disruption 320: Binding of SARS-CoV-2 to ACE2 receptor leading to acute respiratory distress associated mortality 379: Binding to ACE2 leading to thrombosis and disseminated intravascular coagulation 468: Binding of SARS-CoV-2 to ACE2 leads to hyperinflammation (via cell death)
1869	Diminished protective oxidative stress response Short Name Diminished Protective Response to ROS	3	Cellular	Apr 20, 2021	Oct 30, 2023	5 AOPs 379: Binding to ACE2 leading to thrombosis and disseminated intravascular coagulation 406: SARS-CoV-2 infection leading to hyperinflammation 407: SARS-CoV-2 infection leading to pyroptosis 377: Dysregulated prolonged Toll Like Receptor 9 (TLR9) activation leading to Multi Organ Failure involving Acute Respiratory Distress Syndrome (ARDS) 488: Increased reactive oxygen species production leading to decreased cognitive function
54	Up Regulation, CD36 Short Name Up Regulation, CD36	1	Molecular	Nov 29, 2016	Mar 26, 2024	5 AOPs 34: LXR activation leading to hepatic steatosis 58: NR1I3 (CAR) suppression leading to hepatic steatosis 57: AhR activation leading to hepatic steatosis 60: NR1I2 (Pregnane X Receptor, PXR) activation leading to hepatic steatosis 517: Pregnane X Receptor (PXR) activation leads to liver steatosis
10	Acetylcholine accumulation in synapses Short Name ACh Synaptic Accumulation	1	Cellular	Nov 29, 2016	Jun 26, 2020	5 AOPs 16: Acetylcholinesterase inhibition leading to acute mortality 281: Acetylcholinesterase Inhibition Leading to Neurodegeneration 312: Acetylcholinesterase Inhibition leading to Acute Mortality via Impaired Coordination & Movement 405: Organo-Phosphate Chemicals induced inhibition of AChE leading to impaired cognitive function 471: Neuron defect induced early behavioral change
87	Release, Cytokine Short Name Release, Cytokine	1	Cellular	Nov 29, 2016	Sep 16, 2017	5 AOPs 27: Cholestatic Liver Injury induced by Inhibition of the Bile Salt Export Pump (ABCB11) 303: Frustrated phagocytosis-induced lung cancer 377: Dysregulated prolonged Toll Like Receptor 9 (TLR9) activation leading to Multi Organ Failure involving Acute Respiratory Distress Syndrome (ARDS) 412: Endothelial cell dysfunction leading to thromboinflammation 638: Co-exposure to microplastics and cadmium leading to progression from NAFLD to liver tumorigenesis
79	Inhibition, Cyclooxygenase activity Short Name Inhibition, Cyclooxygenase activity	2	Molecular	Nov 29, 2016	Sep 16, 2017	6 AOPs 28: Cyclooxygenase inhibition leading reproductive failure 100: Cyclooxygenase inhibition leading to reproductive dysfunction via inhibition of female spawning behavior 101: Cyclooxygenase inhibition leading to reproductive dysfunction via inhibition of pheromone release 103: Cyclooxygenase inhibition leading to reproductive dysfunction via interference with spindle assembly checkpoint 63: Cyclooxygenase inhibition leading to reproductive dysfunction 102: Cyclooxygenase inhibition leading to reproductive dysfunction via interference with meiotic prophase I /metaphase I transition
134	Increase, Kupffer cell activation Short Name Increase, Kupffer cell activation	1	Cellular	Nov 29, 2016	Feb 11, 2026	6 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
25	Agonism, Androgen receptor Short Name Agonism, Androgen receptor	1	Molecular	Nov 29, 2016	Nov 5, 2024	6 AOPs 23: Androgen receptor agonism leading to reproductive dysfunction (in repeat-spawning fish) 376: Androgen receptor agonism leading to male-biased sex ratio 496: Androgen receptor agonism leading to reproduction dysfunction （in zebrafish） 547: Androgen receptor agonism leading to long anogenital distance (AGD) in female offspring 117: Androgen receptor activation leading to hepatocellular adenomas and carcinomas (in mouse and rat) 495: Androgen receptor activation leading to prostate cancer
2108	Altered, white brain matter Short Name Altered, white brain matter	0	Tissue	Feb 21, 2023	Feb 21, 2023	6 AOPs 485: Thyroid hormone antagonism leading to impaired oligodendrocyte maturation during development and subsequent decreased cognition 487: Unknown MIE altering cholesterol metabolism leading to decreased cognition 488: Increased reactive oxygen species production leading to decreased cognitive function 489: Inhibition of voltage-gated sodium channels leading to decreased cognition 525: Reduced oligodendrocyte differentiation during neurodevelopment leading to impaired learning and memory 610: Decreased thyroid hormone levels in the brain regulated via transport, metabolism and TR activation leading to decreased cognition and motor function
1532	Decrease, Cardiac contractility Short Name Decrease, Cardiac contractility	0	Organ	Jun 19, 2018	Jun 19, 2018	6 AOPs 261: L-type calcium channel blockade leading to heart failure via decrease in cardiac contractility 479: Mitochondrial complexes inhibition leading to left ventricular function decrease via increased myocardial oxidative stress 480: Mitochondrial complexes inhibition leading to heart failure via decreased ATP production 553: Inhibition of Voltage-gated sodium channels (Na⁺ channels) leading to heart failure 556: Decreased Na/K ATPase activity leading to heart failure 558: Phosphodiesterase inhibition leading to heart failure
1669	Increased, DNA damage and mutation Short Name Increased, DNA damage and mutation	5	Cellular	Jul 3, 2019	Aug 13, 2019	6 AOPs 303: Frustrated phagocytosis-induced lung cancer 409: Frustrated phagocytosis leads to malignant mesothelioma 416: Aryl hydrocarbon receptor activation leading to lung cancer through IL-6 toxicity pathway 417: Aryl hydrocarbon receptor activation leading to lung cancer through AHR-ARNT toxicity pathway 443: DNA damage and mutations leading to Metastatic Breast Cancer 451: Interaction with lung resident cell membrane components leads to lung cancer
1613	Decrease, dihydrotestosterone (DHT) levels Short Name Decrease, DHT level	1	Tissue	Apr 10, 2019	Mar 20, 2026	6 AOPs 288: Inhibition of 17α-hydrolase/C 10,20-lyase (Cyp17A1) activity leads to birth reproductive defects (cryptorchidism) in male (mammals) 289: Inhibition of 5α-reductase leading to decreased population growth rate via impaired fecundity in female fish 305: 5α-reductase inhibition leading to short anogenital distance (AGD) in male (mammalian) offspring 527: Decreased, Chicken Ovalbumin Upstream Promoter Transcription Factor II (COUP-TFII) leads to Hypospadias, increased 571: 5α-reductase inhibition leading to hypospadias in male (mammalian) offspring 576: 5α-reductase inhibition leading to increased nipple retention (NR) in male (rodent) offspring
1330	Decreased, neuroplasticity Short Name Decreased, neuroplasticity	0	Molecular	Apr 13, 2017	Nov 10, 2025	6 AOPs 214: Network of SSRIs (selective serotonin reuptake inhibitors) 221: Mental stress to depression 222: Mental stress to agitation 225: Serotonin transporter activation to agitation 224: Serotonin transporter activation to depression 604: Binding of Alpha 1-Adrenergics to Agonists Leading to Depression
1758	Impaired, Spermatogenesis Short Name Impaired, Spermatogenesis	1	Organ	Apr 16, 2020	Jul 28, 2026	6 AOPs 323: PPARalpha Agonism Leading to Decreased Viable Offspring via Decreased 11-Ketotestosterone 348: Inhibition of 11β-Hydroxysteroid Dehydrogenase leading to decreased population trajectory 521: Essential element imbalance leads to reproductive failure via oxidative stress 526: Decreased, Chicken Ovalbumin Upstream Promoter Transcription Factor II (COUP-TFII) leads to Impaired, Spermatogenesis 595: Emerging OPFRS reproductive outcome pathway 651: Suppression, Estrogen receptor (ER) activity leads to Impaired, Spermatogenesis via epigenetic modifications
1047	Increased, secretion of GnRH from hypothalamus Short Name	1	Cellular	Nov 29, 2016	Apr 6, 2026	6 AOPs 165: Antiestrogen activity leading to ovarian adenomas and granular cell tumors in the mouse 440: Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia 623: Activation, estrogen receptor alpha leads to persistent vaginal cornification via increased kisspeptin release 637: Activation, estrogen receptor alpha leads to increased uterine weight via earlier proliferation of cells of the uterine lining 639: Activation, estrogen receptor alpha leads to precocious puberty via increased kisspeptin release 640: Activation, estrogen receptor alpha leads to decreased fertility via prolonged estrus cycle
1928	increased，Vascular endothelial dysfunction Short Name	0	Tissue	Aug 19, 2021	Sep 1, 2021	6 AOPs 507: Nrf2 inhibition leading to vascular disrupting effects via inflammation pathway 508: Nrf2 inhibition leading to vascular disrupting effects through activating HIF1α, Semaphorin 6A, and Dll4-Notch pathway 509: Nrf2 inhibition leading to vascular disrupting effects through activating apoptosis signal pathway and mitochondrial dysfunction 510: Demethylation of PPAR promotor leading to vascular disrupting effects 511: The AOP framework on ROS-mediated oxidative stress induced vascular disrupting effects 538: Adverse outcome pathway of PFAS-induced vascular disrupting effects via activating oxidative stress related pathways
465	Increased, Fatty acid influx Short Name Increased, FA Influx	1	Cellular	Nov 29, 2016	Feb 24, 2026	6 AOPs 57: AhR activation leading to hepatic steatosis 60: NR1I2 (Pregnane X Receptor, PXR) activation leading to hepatic steatosis 58: NR1I3 (CAR) suppression leading to hepatic steatosis 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress
619	Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) Short Name	2	Molecular	Nov 29, 2016	Feb 24, 2025	6 AOPs 97: 5-hydroxytryptamine transporter (5-HTT; SERT) inhibition leading to population decline 98: 5-hydroxytryptamine transporter (5-HTT; SERT) inhibition leading to decreased shelter seeking and increased predation 195: 5-hydroxytryptamine transporter (5-HTT) inhibition leading to population increase 203: 5-hydroxytryptamine transporter inhibition leading to decreased reproductive success and population decline 204: 5-hydroxytryptamine transporter inhibition leading to increased reproductive success and population increase 568: Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to Inhibition, Feeding
2161	Increase, Vascular disrupting effects Short Name Increase, Vascular disrupting effects	0	Individual	Aug 19, 2023	Aug 19, 2023	6 AOPs 507: Nrf2 inhibition leading to vascular disrupting effects via inflammation pathway 508: Nrf2 inhibition leading to vascular disrupting effects through activating HIF1α, Semaphorin 6A, and Dll4-Notch pathway 509: Nrf2 inhibition leading to vascular disrupting effects through activating apoptosis signal pathway and mitochondrial dysfunction 510: Demethylation of PPAR promotor leading to vascular disrupting effects 511: The AOP framework on ROS-mediated oxidative stress induced vascular disrupting effects 538: Adverse outcome pathway of PFAS-induced vascular disrupting effects via activating oxidative stress related pathways
2405	Increase, Hepatocellular lipotoxicity Short Name Increase, Hepatocellular lipotoxicity	0	Cellular	Feb 10, 2026	Feb 10, 2026	6 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
2406	Increase, Regenerative nodule formation Short Name Increase, Regenerative nodule formation	0	Tissue	Feb 10, 2026	Feb 10, 2026	6 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
2407	Increase, Cirrhosis Short Name Increase, Cirrhosis	0	Organ	Feb 10, 2026	Feb 11, 2026	6 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
2410	Increase, 11β-Hydroxysteroid dehydrogenase type 1 activity Short Name Increase, 11β-HSD1 activity	0	Molecular	Feb 18, 2026	Feb 18, 2026	6 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress